Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension

a technology for cirrhosis and patients, applied in the field of methods, can solve the problems of increasing the inflow of portal veins, contributing to the hypertension of portals, and the technique is invasive, and is available only in expert centres

Inactive Publication Date: 2016-11-15
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a method to determine if a patient with cirrhosis is at risk of having significant portal hypertension. This is done by measuring the levels of specific microparticles in a blood sample from the patient and comparing them to predetermined reference values. A difference between the levels measured and the reference values indicates the patient's risk for clinical significance of portal hypertension.

Problems solved by technology

In cirrhosis, abnormal persistent vasodilation of arterial vessels leads to increased portal venous inflow and contributes to portal hypertension.
However, this technique is invasive and available only in expert centres.
However, little is known about these factors, and more importantly, the mechanisms leading to vascular hypocontractility have not yet been elucidated1.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
  • Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
  • Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension

Examples

Experimental program
Comparison scheme
Effect test

example 1

Abnormal Plasma Microparticle Levels Impair Vasoconstrictor Responses in Cirrhosis

[0031]Material & Methods

[0032]Patients and Controls

[0033]We included 91 patients admitted to the Liver Unit (Hôpital Beaujon, Clichy, France) for alcoholic and / or hepatitis C virus related cirrhosis during two periods of time: between 2007 and 2008, 26 patients (the pilot cohort); and between 2010 and 2011, 65 additional patients. None of the patients had severe sepsis, hepatocellular carcinoma assessed using serum alpha-fetoprotein level and CT-scan or ultrasonography, or portal vein thrombosis. The pilot cohort was compared to a group of 30 healthy volunteer subjects. All patients and controls gave their informed consent to participate to the study. The study conformed to the ethical guidelines of the 1975 declaration of Helsinki.

[0034]Isolation of Circulating MPs

[0035]Circulating MPs were isolated from platelet-free plasma obtained by successive centrifugations of venous blood as reported earlier5. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+ / 41−), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension.BACKGROUND OF THE INVENTION[0002]In cirrhosis, abnormal persistent vasodilation of arterial vessels leads to increased portal venous inflow and contributes to portal hypertension. Indeed, portal hypertension is determined by both the degree of hepatic outflow resistance, related to liver architecture changes, and the extent of inflow into the portal venous system from the splanchnic bed. Portal hypertension is a major factor in the development of complications of cirrhosis, and as arterial vasodilation associated with portal hypertension is potentially reversible, understanding its mechanisms is of great therapeutic interest1. The gold-standard for assessing portal hypertension is currently hepatic venous pressure gradient measurement. However, this technique is invasive and available only in ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): G01N33/68G01N33/569
CPCG01N33/6893G01N33/56966G01N2333/4742G01N2333/70503G01N2333/70514G01N2333/70553G01N2333/70596G01N2800/085
Inventor RAUTOU, PIERRE-EMMANUELBOULANGER, CHANTALVALLA, DOMINIQUE-CHARLES
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com